Progress of companion diagnostics in chimeric antigen receptor T-cell therapy / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 501-505, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-989011
ABSTRACT
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved good efficacy in treatment of hematological malignancies. As a precise and individualized treatment method, CAR-T is gradually moving towards commercialization. In addition to the introduction of corresponding policies and guiding principles, the related detection protocols should also be updated and improved to maximize its effect and achieve precise individualization. This article introduces and expands the concept of "companion diagnostics" that first appeared in targeted drugs, and introduces the significances of various detection technologies and biomarkers for patient screening, safety monitoring and evaluation of efficacy and CAR-T function in the whole process of CAR-T treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS